Research led by The Australian National University (ANU) has found doctors around the world are over diagnosing the most common thyroid cancer, creating an artificial epidemic that costs billions of dollars each year in unnecessary ...
Sep 6, 2016
0
107
Papillary thyroid cancer accounts for the majority of all thyroid malignancies, which primarily impact women. A new study indicates that routinely removing lymph nodes in the neck in these cancer patients may help prevent ...
Dec 20, 2011
0
0
Despite tens of thousands of studies in the literature on the thyroid gland, thyroid hormone, and thyroid disease, lack of standardization in study design makes it difficult to compare the results and apply them to the development ...
Sep 5, 2013
0
0
Women who survived breast or thyroid cancer faced an elevated risk of developing the other cancer as a secondary malignancy, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the ...
Feb 5, 2016
0
32
Hospital price transparency is intended to help inform patients about the cost of services and procedures before they receive them. Since Jan. 1, 2021, hospitals in the U.S. have been required by The Centers for Medicare ...
Jun 4, 2021
0
2
As the rate of thyroid cancer continues to climb, doctors are urging patients to be more cautious about thyroid nodules, a common disorder that is responsible for a small but growing number of thyroid cancer cases. Thyroid ...
Aug 9, 2011
0
0
New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. In addition, certain subgroups of patients have an especially ...
Dec 17, 2018
0
43
Obesity increases the risk of developing a number of cancers, so it stands to reason that drugs that reduce body weight should also reduce the risk of developing these cancers.
Jul 13, 2024
0
1
A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme, researchers at Winship Cancer Institute of Emory University have discovered.
Jul 2, 2015
0
107
The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type, according to results from the international ...
Aug 12, 2022
0
36
